{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,18]],"date-time":"2026-11-18T08:21:03Z","timestamp":1794990063636,"version":"4.9.1"},"reference-count":69,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T00:00:00Z","timestamp":1760572800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T00:00:00Z","timestamp":1760572800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000060","name":"U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["R01 AI143773"],"award-info":[{"award-number":["R01 AI143773"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["T32 AI07140"],"award-info":[{"award-number":["T32 AI07140"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006108","name":"U.S. Department of Health & Human Services | NIH | National Center for Advancing Translational Sciences","doi-asserted-by":"publisher","award":["U18 TR0033208"],"award-info":[{"award-number":["U18 TR0033208"]}],"id":[{"id":"10.13039\/100006108","id-type":"DOI","asserted-by":"publisher"}]},{"name":"NIH Intramural Research Program and Cure Acceleration Network Program to NCATS"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Herpes simplex virus (HSV) infection poses global public health concerns with lifelong impacts. Acyclovir, the standard therapy, has limited efficacy in preventing subclinical shedding, and drug resistance occurs in immunocompromised patients, highlighting the need for novel therapeutics. Here we show that acyclovir is significantly less effective in skin-derived keratinocytes than donor-matched fibroblasts. Using 3D bioprinted human skin equivalents (HSEs) in a 96-well plate format, we have screened 738 compounds with broad targets and mechanisms of action, identifying potent antivirals, including 23 known or experimental HSV treatments. Unlike acyclovir, antivirals against HSV helicase\/primase or host replication pathways display similar potency across cell types and donor sources in both 2D and 3D models. The reduced potency in keratinocytes may explain acyclovir\u2019s limited clinical efficacy. Our 3D bioprinted HSE assay platform enables the integration of patient-derived cells early in drug development and offers a physiologically relevant approach for HSV drug discovery.<\/jats:p>","DOI":"10.1038\/s41467-025-64245-w","type":"journal-article","created":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T09:16:40Z","timestamp":1760606200000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Limitations of acyclovir and identification of potent HSV antivirals using 3D bioprinted human skin equivalents"],"prefix":"10.1038","volume":"16","author":[{"given":"S. Tori","family":"Ellison","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ian","family":"Hayman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristy","family":"Derr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paige","family":"Derr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shayne","family":"Frebert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zina","family":"Itkin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony","family":"Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wendy","family":"Olson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2179-2436","authenticated-orcid":false,"given":"Lawrence","family":"Corey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3486-6438","authenticated-orcid":false,"given":"Anna","family":"Wald","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3073-0843","authenticated-orcid":false,"given":"Christine","family":"Johnston","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4230-6863","authenticated-orcid":false,"given":"Youyi","family":"Fong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4569-9137","authenticated-orcid":false,"given":"Marc","family":"Ferrer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8676-5105","authenticated-orcid":false,"given":"Jia","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,16]]},"reference":[{"key":"64245_CR1","doi-asserted-by":"publisher","first-page":"e0140765","DOI":"10.1371\/journal.pone.0140765","volume":"10","author":"KJ Looker","year":"2015","unstructured":"Looker, K. J. et al. Global and regional estimates of prevalent and incident herpes simplex virus type 1 infections in 2012. PLoS One 10, e0140765 (2015).","journal-title":"PLoS One"},{"key":"64245_CR2","doi-asserted-by":"publisher","first-page":"e114989","DOI":"10.1371\/journal.pone.0114989","volume":"10","author":"KJ Looker","year":"2015","unstructured":"Looker, K. J. et al. Global estimates of prevalent and incident herpes simplex virus type 2 infections in 2012. PLoS One 10, e114989 (2015).","journal-title":"PLoS One"},{"key":"64245_CR3","doi-asserted-by":"publisher","first-page":"2127","DOI":"10.1016\/S0140-6736(07)61908-4","volume":"370","author":"R Gupta","year":"2007","unstructured":"Gupta, R., Warren, T. & Wald, A. Genital herpes. Lancet 370, 2127\u20132137 (2007).","journal-title":"Lancet"},{"key":"64245_CR4","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1016\/j.idc.2015.05.001","volume":"29","author":"SH James","year":"2015","unstructured":"James, S. H. & Kimberlin, D. W. Neonatal herpes simplex virus infection. Infect. Dis. Clin. North Am. 29, 391\u2013400 (2015).","journal-title":"Infect. Dis. Clin. North Am."},{"key":"64245_CR5","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1097\/00126334-200404150-00001","volume":"35","author":"L Corey","year":"2004","unstructured":"Corey, L., Wald, A., Celum, C. L. & Quinn, T. C. The effects of herpes simplex virus-2 on HIV-1 acquisition and transmission: a review of two overlapping epidemics. J. Acquir Immune Defic. Syndr. 35, 435\u2013445 (2004).","journal-title":"J. Acquir Immune Defic. Syndr."},{"key":"64245_CR6","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1097\/01.aids.0000198081.09337.a7","volume":"20","author":"EE Freeman","year":"2006","unstructured":"Freeman, E. E. et al. Herpes simplex virus 2 infection increases HIV acquisition in men and women: systematic review and meta-analysis of longitudinal studies. AIDS 20, 73\u201383 (2006).","journal-title":"AIDS"},{"key":"64245_CR7","doi-asserted-by":"publisher","first-page":"e2230","DOI":"10.1371\/journal.pone.0002230","volume":"3","author":"LJ Abu-Raddad","year":"2008","unstructured":"Abu-Raddad, L. J. et al. Genital herpes has played a more important role than any other sexually transmitted infection in driving HIV prevalence in Africa. PLoS One 3, e2230 (2008).","journal-title":"PLoS One"},{"key":"64245_CR8","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1016\/S1473-3099(19)30470-0","volume":"20","author":"KJ Looker","year":"2020","unstructured":"Looker, K. J. et al. Global and regional estimates of the contribution of herpes simplex virus type 2 infection to HIV incidence: a population attributable fraction analysis using published epidemiological data. Lancet Infect. Dis. 20, 240\u2013249 (2020).","journal-title":"Lancet Infect. Dis."},{"key":"64245_CR9","doi-asserted-by":"publisher","first-page":"1652","DOI":"10.1056\/NEJMoa011915","volume":"347","author":"LR Stanberry","year":"2002","unstructured":"Stanberry, L. R. et al. Glycoprotein-D-adjuvant vaccine to prevent genital herpes. N. Engl. J. Med. 347, 1652\u20131661 (2002).","journal-title":"N. Engl. J. Med."},{"key":"64245_CR10","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1126\/science.330.6002.304","volume":"330","author":"J Cohen","year":"2010","unstructured":"Cohen, J. Immunology. Painful failure of promising genital herpes vaccine. Science 330, 304 (2010).","journal-title":"Science"},{"key":"64245_CR11","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1056\/NEJMoa1103151","volume":"366","author":"RB Belshe","year":"2012","unstructured":"Belshe, R. B. et al. Efficacy results of a trial of a herpes simplex vaccine. N. Engl. J. Med 366, 34\u201343 (2012).","journal-title":"N. Engl. J. Med"},{"key":"64245_CR12","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1016\/S0190-9622(88)70022-5","volume":"18","author":"DH King","year":"1988","unstructured":"King, D. H. History, pharmacokinetics, and pharmacology of acyclovir. J. Am. Acad. Dermatol 18, 176\u2013179 (1988).","journal-title":"J. Am. Acad. Dermatol"},{"key":"64245_CR13","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1128\/CMR.16.1.114-128.2003","volume":"16","author":"TH Bacon","year":"2003","unstructured":"Bacon, T. H., Levin, M. J., Leary, J. J., Sarisky, R. T. & Sutton, D. Herpes simplex virus resistance to acyclovir and penciclovir after two decades of antiviral therapy. Clin. Microbiol Rev. 16, 114\u2013128 (2003).","journal-title":"Clin. Microbiol Rev."},{"key":"64245_CR14","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1016\/j.antiviral.2010.03.002","volume":"86","author":"A Sauerbrei","year":"2010","unstructured":"Sauerbrei, A., Deinhardt, S., Zell, R. & Wutzler, P. Phenotypic and genotypic characterization of acyclovir-resistant clinical isolates of herpes simplex virus. Antivir. Res 86, 246\u2013252 (2010).","journal-title":"Antivir. Res"},{"key":"64245_CR15","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1016\/S0140-6736(11)61750-9","volume":"379","author":"C Johnston","year":"2012","unstructured":"Johnston, C. et al. Standard-dose and high-dose daily antiviral therapy for short episodes of genital HSV-2 reactivation: Three randomised, open-label, cross-over trials. Lancet 379, 641\u2013647 (2012).","journal-title":"Lancet"},{"key":"64245_CR16","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1056\/NEJMoa0904849","volume":"362","author":"C Celum","year":"2010","unstructured":"Celum, C. et al. Acyclovir and transmission of HIV-1 from persons infected with HIV-1 and HSV-2. N. Engl. J. Med 362, 427\u2013439 (2010).","journal-title":"N. Engl. J. Med"},{"key":"64245_CR17","doi-asserted-by":"publisher","first-page":"886","DOI":"10.1038\/nm.2006","volume":"15","author":"J Zhu","year":"2009","unstructured":"Zhu, J. et al. Persistence of HIV-1 receptor-positive cells after HSV-2 reactivation is a potential mechanism for increased HIV-1 acquisition. Nat. Med. 15, 886\u2013892 (2009).","journal-title":"Nat. Med."},{"key":"64245_CR18","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1177\/1535370214538747","volume":"239","author":"NJ Eungdamrong","year":"2014","unstructured":"Eungdamrong, N. J. et al. Challenges and promises in modeling dermatologic disorders with bioengineered skin. Exp. Biol. Med. (Maywood) 239, 1215\u20131224 (2014).","journal-title":"Exp. Biol. Med. (Maywood)"},{"key":"64245_CR19","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1038\/nrd4539","volume":"14","author":"EW Esch","year":"2015","unstructured":"Esch, E. W., Bahinski, A. & Huh, D. Organs-on-chips at the frontiers of drug discovery. Nat. Rev. Drug Discov. 14, 248\u2013260 (2015).","journal-title":"Nat. Rev. Drug Discov."},{"key":"64245_CR20","doi-asserted-by":"publisher","first-page":"1174","DOI":"10.1177\/2472555220923332","volume":"25","author":"JE Ekert","year":"2020","unstructured":"Ekert, J. E. et al. Recommended guidelines for developing, qualifying, and implementing complex in vitro models (CIVMs) for drug discovery. SLAS Discov. 25, 1174\u20131190 (2020).","journal-title":"SLAS Discov."},{"key":"64245_CR21","first-page":"114","volume":"6","author":"IW Mak","year":"2014","unstructured":"Mak, I. W., Evaniew, N. & Ghert, M. Lost in translation: Animal models and clinical trials in cancer treatment. Am. J. Transl. Res. 6, 114\u2013118 (2014).","journal-title":"Am. J. Transl. Res."},{"key":"64245_CR22","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1038\/nrd3681","volume":"11","author":"JW Scannell","year":"2012","unstructured":"Scannell, J. W., Blanckley, A., Boldon, H. & Warrington, B. Diagnosing the decline in pharmaceutical R&D efficiency. Nat. Rev. Drug Discov. 11, 191\u2013200 (2012).","journal-title":"Nat. Rev. Drug Discov."},{"key":"64245_CR23","doi-asserted-by":"publisher","first-page":"1877","DOI":"10.1056\/NEJMp1500848","volume":"372","author":"J Avorn","year":"2015","unstructured":"Avorn, J. The $2.6 billion pill-methodologic and policy considerations. N. Engl. J. Med. 372, 1877\u20131879 (2015).","journal-title":"N. Engl. J. Med."},{"key":"64245_CR24","doi-asserted-by":"crossref","unstructured":"Gopallawa, I. et al. Applications of organoids in advancing drug discovery and development. J. Pharm. Sci. (2024).","DOI":"10.1016\/j.xphs.2024.06.016"},{"key":"64245_CR25","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1038\/nbt.2989","volume":"32","author":"SN Bhatia","year":"2014","unstructured":"Bhatia, S. N. & Ingber, D. E. Microfluidic organs-on-chips. Nat. Biotechnol. 32, 760\u2013772 (2014).","journal-title":"Nat. Biotechnol."},{"key":"64245_CR26","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1016\/j.tcb.2011.09.005","volume":"21","author":"D Huh","year":"2011","unstructured":"Huh, D., Hamilton, G. A. & Ingber, D. E. From 3D cell culture to organs-on-chips. Trends Cell Biol. 21, 745\u2013754 (2011).","journal-title":"Trends Cell Biol."},{"key":"64245_CR27","doi-asserted-by":"crossref","unstructured":"Gauglitz G. G., Schauber J. Skin: Architecture and Function. In: Kamolz L.-P., Lumenta D. B., editors. Dermal Replacements in General, Burn, and Plastic Surgery: Tissue Engineering in Clinical Practice. Vienna: Springer Vienna; p. 1-11. (2013)","DOI":"10.1007\/978-3-7091-1586-2_1"},{"key":"64245_CR28","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1084\/jem.20061792","volume":"204","author":"J Zhu","year":"2007","unstructured":"Zhu, J. et al. Virus-specific CD8+ T cells accumulate near sensory nerve endings in genital skin during subclinical HSV-2 reactivation. J. Exp. Med 204, 595\u2013603 (2007).","journal-title":"J. Exp. Med"},{"key":"64245_CR29","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-33114-1","volume":"13","author":"S Sun","year":"2022","unstructured":"Sun, S., Jin, L., Zheng, Y. & Zhu, J. Modeling human HSV infection via a vascularized immune-competent skin-on-chip platform. Nat. Commun. 13, 5481 (2022).","journal-title":"Nat. Commun."},{"key":"64245_CR30","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1089\/ten.tec.2018.0318","volume":"25","author":"K Derr","year":"2019","unstructured":"Derr, K. et al. Fully three-dimensional bioprinted skin equivalent constructs with validated morphology and barrier function. Tissue Eng. Part C. Methods 25, 334\u2013343 (2019).","journal-title":"Tissue Eng. Part C. Methods"},{"key":"64245_CR31","doi-asserted-by":"publisher","first-page":"035002","DOI":"10.1088\/1758-5090\/ab76a1","volume":"12","author":"X Liu","year":"2020","unstructured":"Liu, X., Michael, S., Bharti, K., Ferrer, M. & Song, M. J. A biofabricated vascularized skin model of atopic dermatitis for preclinical studies. Biofabrication 12, 035002 (2020).","journal-title":"Biofabrication"},{"key":"64245_CR32","unstructured":"Roizman B., Knipe D. M., Howley P. M. Herpes simplex viruses. In: Knipe D. M., Howley P. M., editors. Field\u2019s Virology. 6th ed. The Netherlands: Wolters K. Alphen aan den Rijn; (2014)."},{"key":"64245_CR33","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1038\/nature12110","volume":"497","author":"J Zhu","year":"2013","unstructured":"Zhu, J. et al. Immune surveillance by CD8alphaalpha+ skin-resident T cells in human herpes virus infection. Nature 497, 494\u2013497 (2013).","journal-title":"Nature"},{"key":"64245_CR34","doi-asserted-by":"publisher","first-page":"5716","DOI":"10.1073\/pnas.74.12.5716","volume":"74","author":"GB Elion","year":"1977","unstructured":"Elion, G. B. et al. Selectivity of action of an antiherpetic agent, 9-(2-hydroxyethoxymethyl) guanine. Proc. Natl. Acad. Sci. USA 74, 5716\u20135720 (1977).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"64245_CR35","doi-asserted-by":"publisher","first-page":"2438","DOI":"10.1128\/AAC.47.8.2438-2441.2003","volume":"47","author":"J Lycke","year":"2003","unstructured":"Lycke, J., Malmestrom, C. & Stahle, L. Acyclovir levels in serum and cerebrospinal fluid after oral administration of valacyclovir. Antimicrob. Agents Chemother. 47, 2438\u20132441 (2003).","journal-title":"Antimicrob. Agents Chemother."},{"key":"64245_CR36","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1038\/nprot.2006.448","volume":"2","author":"P Gangatirkar","year":"2007","unstructured":"Gangatirkar, P., Paquet-Fifield, S., Li, A., Rossi, R. & Kaur, P. Establishment of 3D organotypic cultures using human neonatal epidermal cells. Nat. Protoc. 2, 178\u2013186 (2007).","journal-title":"Nat. Protoc."},{"key":"64245_CR37","unstructured":"Ling-juan Z. Keratins in Skin Epidermal Development and Diseases. In: Miroslav B., editor. Keratin. Rijeka: IntechOpen; p. Ch. 5. (2018)"},{"key":"64245_CR38","doi-asserted-by":"publisher","first-page":"7563","DOI":"10.1128\/JVI.72.9.7563-7568.1998","volume":"72","author":"P Desai","year":"1998","unstructured":"Desai, P. & Person, S. Incorporation of the green fluorescent protein into the herpes simplex virus type 1 capsid. J. Virol. 72, 7563\u20137568 (1998).","journal-title":"J. Virol."},{"key":"64245_CR39","unstructured":"Iversen PWBB, et al. HTS Assay Validation. In: Assay Guidance Manual [Internet] [Internet]. Bethesda, MD: Eli Lily & Company and the National Centers for Advancing Translational Research. Available from: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK83783\/. (2012)"},{"key":"64245_CR40","unstructured":"Taylor M., Gerriets V. Acyclovir. StatPearls. Treasure Island (FL) (2024)."},{"key":"64245_CR41","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1128\/CMR.16.4.569-596.2003","volume":"16","author":"E De Clercq","year":"2003","unstructured":"De Clercq, E. Clinical potential of the acyclic nucleoside phosphonates cidofovir, adefovir, and tenofovir in treatment of DNA virus and retrovirus infections. Clin. Microbiol Rev. 16, 569\u2013596 (2003).","journal-title":"Clin. Microbiol Rev."},{"key":"64245_CR42","doi-asserted-by":"publisher","first-page":"1733","DOI":"10.1093\/jac\/dkq198","volume":"65","author":"K Chono","year":"2010","unstructured":"Chono, K. et al. ASP2151, a novel helicase-primase inhibitor, possesses antiviral activity against varicella-zoster virus and herpes simplex virus types 1 and 2. J. Antimicrob. Chemother. 65, 1733\u20131741 (2010).","journal-title":"J. Antimicrob. Chemother."},{"key":"64245_CR43","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-12894-z","volume":"10","author":"E Wyler","year":"2019","unstructured":"Wyler, E. et al. Single-cell RNA-sequencing of herpes simplex virus 1-infected cells connects NRF2 activation to an antiviral program. Nat. Commun. 10, 4878 (2019).","journal-title":"Nat. Commun."},{"key":"64245_CR44","doi-asserted-by":"publisher","unstructured":"Schneider S. M., Pritchard S. M., Wudiri G. A., Trammell C. E., Nicola A. V. Early steps in herpes simplex virus infection blocked by a proteasome inhibitor. mBio. 10. Epub 20190514. https:\/\/doi.org\/10.1128\/mBio.00732-19 (2019)","DOI":"10.1128\/mBio.00732-19"},{"key":"64245_CR45","doi-asserted-by":"publisher","first-page":"365","DOI":"10.2220\/biomedres.30.365","volume":"30","author":"C Ushio","year":"2009","unstructured":"Ushio, C. et al. Suppressive effects of a cyanine dye against herpes simplex virus (HSV)\u22121 infection. Biomed. Res 30, 365\u2013368 (2009).","journal-title":"Biomed. Res"},{"key":"64245_CR46","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1038\/nm0402-392","volume":"8","author":"G Kleymann","year":"2002","unstructured":"Kleymann, G. et al. New helicase-primase inhibitors as drug candidates for the treatment of herpes simplex disease. Nat. Med. 8, 392\u2013398 (2002).","journal-title":"Nat. Med."},{"key":"64245_CR47","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1099\/0022-1317-79-1-117","volume":"79","author":"CM Preston","year":"1998","unstructured":"Preston, C. M., Rinaldi, A. & Nicholl, M. J. Herpes simplex virus type 1 immediate early gene expression is stimulated by inhibition of protein synthesis. J. Gen. Virol. 79, 117\u2013124 (1998).","journal-title":"J. Gen. Virol."},{"key":"64245_CR48","doi-asserted-by":"publisher","unstructured":"Andersen P. I. et al. Novel antiviral activities of obatoclax, emetine, niclosamide, brequinar, and homoharringtonine. Viruses 11. https:\/\/doi.org\/10.3390\/v11100964 (2019).","DOI":"10.3390\/v11100964"},{"key":"64245_CR49","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1177\/135965350601100805","volume":"11","author":"S La Frazia","year":"2006","unstructured":"La Frazia, S., Amici, C. & Santoro, M. G. Antiviral activity of proteasome inhibitors in herpes simplex virus-1 infection: role of nuclear factor-kappaB. Antivir. Ther. 11, 995\u20131004 (2006).","journal-title":"Antivir. Ther."},{"key":"64245_CR50","first-page":"826","volume":"21","author":"MD Trousdale","year":"1981","unstructured":"Trousdale, M. D., Nesburn, A. B., Watanabe, K. A. & Fox, J. J. Evaluation of the antiherpetic activity of 2\u2019-fluoro-5-iodo-ara-C in rabbit eyes and cell cultures. Invest Ophthalmol. Vis. Sci. 21, 826\u2013832 (1981).","journal-title":"Invest Ophthalmol. Vis. Sci."},{"key":"64245_CR51","doi-asserted-by":"publisher","first-page":"1282","DOI":"10.1016\/j.clinthera.2018.07.006","volume":"40","author":"CL Poole","year":"2018","unstructured":"Poole, C. L. & James, S. H. Antiviral therapies for herpesviruses: Current agents and new directions. Clin. Ther. 40, 1282\u20131298 (2018).","journal-title":"Clin. Ther."},{"key":"64245_CR52","doi-asserted-by":"publisher","first-page":"35324","DOI":"10.1074\/jbc.M112.392142","volume":"287","author":"OV Denisova","year":"2012","unstructured":"Denisova, O. V. et al. Obatoclax, saliphenylhalamide, and gemcitabine inhibit influenza a virus infection. J. Biol. Chem. 287, 35324\u201335332 (2012).","journal-title":"J. Biol. Chem."},{"key":"64245_CR53","doi-asserted-by":"publisher","first-page":"341","DOI":"10.2147\/IJWH.S27601","volume":"4","author":"D Tan","year":"2012","unstructured":"Tan, D. Potential role of tenofovir vaginal gel for reduction of risk of herpes simplex virus in females. Int J. Women\u2019s. Health 4, 341\u2013350 (2012).","journal-title":"Int J. Women\u2019s. Health"},{"key":"64245_CR54","doi-asserted-by":"publisher","first-page":"155308","DOI":"10.1016\/j.phymed.2023.155308","volume":"124","author":"S Wu","year":"2024","unstructured":"Wu, S. et al. Lanatoside C inhibits herpes simplex virus 1 replication by regulating NRF2 distribution within cells. Phytomedicine 124, 155308 (2024).","journal-title":"Phytomedicine"},{"key":"64245_CR55","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-63438-1","volume":"10","author":"H Ishimaru","year":"2020","unstructured":"Ishimaru, H. et al. MG132 exerts anti-viral activity against HSV-1 by overcoming virus-mediated suppression of the ERK signaling pathway. Sci. Rep. 10, 6671 (2020).","journal-title":"Sci. Rep."},{"key":"64245_CR56","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1186\/s12866-019-1639-8","volume":"19","author":"Q Huang","year":"2019","unstructured":"Huang, Q. et al. Antiviral activity of mitoxantrone dihydrochloride against human herpes simplex virus mediated by suppression of the viral immediate early genes. BMC Microbiol 19, 274 (2019).","journal-title":"BMC Microbiol"},{"key":"64245_CR57","doi-asserted-by":"publisher","first-page":"1766","DOI":"10.1128\/AAC.46.6.1766-1772.2002","volume":"46","author":"UA Betz","year":"2002","unstructured":"Betz, U. A., Fischer, R., Kleymann, G., Hendrix, M. & Rubsamen-Waigmann, H. Potent in vivo antiviral activity of the herpes simplex virus primase-helicase inhibitor BAY 57-1293. Antimicrob. Agents Chemother. 46, 1766\u20131772 (2002).","journal-title":"Antimicrob. Agents Chemother."},{"key":"64245_CR58","doi-asserted-by":"publisher","first-page":"4703","DOI":"10.1016\/j.bmcl.2012.05.079","volume":"22","author":"YF Xiang","year":"2012","unstructured":"Xiang, Y. F. et al. Anti-herpes simplex virus efficacies of 2-aminobenzamide derivatives as novel HSP90 inhibitors. Bioorg. Med. Chem. Lett. 22, 4703\u20134706 (2012).","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"64245_CR59","doi-asserted-by":"publisher","first-page":"329","DOI":"10.2165\/00003495-198223050-00001","volume":"23","author":"AA Carmine","year":"1982","unstructured":"Carmine, A. A., Brogden, R. N., Heel, R. C., Speight, T. M. & Avery, G. S. Trifluridine: a review of its antiviral activity and therapeutic use in the topical treatment of viral eye infections. Drugs 23, 329\u2013353 (1982).","journal-title":"Drugs"},{"key":"64245_CR60","doi-asserted-by":"publisher","first-page":"1729","DOI":"10.1001\/archinte.1996.00440140169018","volume":"156","author":"SL Spruance","year":"1996","unstructured":"Spruance, S. L., Tyring, S. K., DeGregorio, B., Miller, C. & Beutner, K. A large-scale, placebo-controlled, dose-ranging trial of peroral valaciclovir for episodic treatment of recurrent herpes genitalis. Valaciclovir HSV Study Group. Arch. Intern Med. 156, 1729\u20131735 (1996).","journal-title":"Arch. Intern Med."},{"key":"64245_CR61","doi-asserted-by":"crossref","unstructured":"Kimberlin D. W., Whitley R. J. Antiviral therapy of HSV-1 and \u22122. In: Human Herpesviruses: Biology, Therapy, and Immunoprophylaxis [Internet]. Cambridge University Press. Available from: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK47444\/. (2007)","DOI":"10.1017\/CBO9780511545313.065"},{"key":"64245_CR62","doi-asserted-by":"publisher","first-page":"5820","DOI":"10.1128\/AAC.01114-13","volume":"57","author":"JT Schiffer","year":"2013","unstructured":"Schiffer, J. T., Swan, D. A., Corey, L. & Wald, A. Rapid viral expansion and short drug half-life explain the incomplete effectiveness of current herpes simplex virus 2-directed antiviral agents. Antimicrob. Agents Chemother. 57, 5820\u20135829 (2013).","journal-title":"Antimicrob. Agents Chemother."},{"key":"64245_CR63","doi-asserted-by":"publisher","first-page":"2759","DOI":"10.1128\/AAC.39.12.2759","volume":"39","author":"J Soul-Lawton","year":"1995","unstructured":"Soul-Lawton, J. et al. Absolute bioavailability and metabolic disposition of valaciclovir, the L-valyl ester of acyclovir, following oral administration to humans. Antimicrob. Agents Chemother. 39, 2759\u20132764 (1995).","journal-title":"Antimicrob. Agents Chemother."},{"key":"64245_CR64","doi-asserted-by":"publisher","first-page":"2109","DOI":"10.1016\/S0140-6736(08)60920-4","volume":"371","author":"C Celum","year":"2008","unstructured":"Celum, C. et al. Effect of aciclovir on HIV-1 acquisition in herpes simplex virus 2 seropositive women and men who have sex with men: A randomised, double-blind, placebo-controlled trial. Lancet 371, 2109\u20132119 (2008).","journal-title":"Lancet"},{"key":"64245_CR65","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s00280-016-3003-0","volume":"78","author":"J Ciccolini","year":"2016","unstructured":"Ciccolini, J., Serdjebi, C., Peters, G. J. & Giovannetti, E. Pharmacokinetics and pharmacogenetics of Gemcitabine as a mainstay in adult and pediatric oncology: an EORTC-PAMM perspective. Cancer Chemother. Pharm. 78, 1\u201312 (2016).","journal-title":"Cancer Chemother. Pharm."},{"key":"64245_CR66","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1093\/hmg\/ddq498","volume":"20","author":"J Li","year":"2011","unstructured":"Li, J., Zhang, L., Zhou, H., Stoneking, M. & Tang, K. Global patterns of genetic diversity and signals of natural selection for human ADME genes. Hum. Mol. Genet 20, 528\u2013540 (2011).","journal-title":"Hum. Mol. Genet"},{"key":"64245_CR67","doi-asserted-by":"publisher","first-page":"113852","DOI":"10.1016\/j.biopha.2022.113852","volume":"156","author":"I Kacirova","year":"2022","unstructured":"Kacirova, I., Urinovska, R. & Sagan, J. Therapeutic monitoring of serum concentrations of acyclovir and its metabolite 9-(carboxymethoxymethyl) guanine in routine clinical practice. Biomed. Pharmacother. 156, 113852 (2022).","journal-title":"Biomed. Pharmacother."},{"key":"64245_CR68","doi-asserted-by":"publisher","first-page":"566607","DOI":"10.3389\/fimmu.2020.566607","volume":"11","author":"P Henrot","year":"2020","unstructured":"Henrot, P. et al. A method for isolating and culturing skin cells: Application to endothelial cells, fibroblasts, keratinocytes, and melanocytes from punch biopsies in systemic sclerosis skin. Front Immunol. 11, 566607 (2020).","journal-title":"Front Immunol."},{"key":"64245_CR69","doi-asserted-by":"publisher","first-page":"1363","DOI":"10.1089\/ten.tea.2009.0339","volume":"16","author":"A Terunuma","year":"2010","unstructured":"Terunuma, A., Limgala, R. P., Park, C. J., Choudhary, I. & Vogel, J. C. Efficient procurement of epithelial stem cells from human tissue specimens using a Rho-associated protein kinase inhibitor Y-27632. Tissue Eng. Part A 16, 1363\u20131368 (2010).","journal-title":"Tissue Eng. Part A"}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-64245-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-64245-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-64245-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T10:04:30Z","timestamp":1760609070000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-64245-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,16]]},"references-count":69,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["64245"],"URL":"https:\/\/doi.org\/10.1038\/s41467-025-64245-w","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,16]]},"assertion":[{"value":"21 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"9200"}}